{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T23:25:17Z","timestamp":1695425117384},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":855,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematol Oncol"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1002\/hon.2054","type":"journal-article","created":{"date-parts":[[2013,4,29]],"date-time":"2013-04-29T06:40:39Z","timestamp":1367217639000},"page":"47-51","source":"Crossref","is-referenced-by-count":6,"title":["Development of an Epstein-Barr virus-associated lymphoproliferative disorder in a patient treated with azacitidine for chronic myelomonocytic leukaemia"],"prefix":"10.1002","volume":"32","author":[{"given":"T","family":"Menter","sequence":"first","affiliation":[{"name":"Institute of Pathology; University Hospital Basel; Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Schlageter","sequence":"additional","affiliation":[{"name":"Institute of Pathology; University Hospital Basel; Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Bastian","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine; University Hospital Basel; Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Haberth\u00fcr","sequence":"additional","affiliation":[{"name":"Practice for Internal Medicine and Oncology; Friedhofstrasse 2 Breitenbach Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AE","family":"R\u00e4tz Bravo","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Toxicology; University Hospital Basel; Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Tzankov","sequence":"additional","affiliation":[{"name":"Institute of Pathology; University Hospital Basel; Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,4,29]]},"reference":[{"issue":"3","key":"10.1002\/hon.2054-BIB0001|hon2054-cit-0001","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1634\/theoncologist.10-3-176","article-title":"FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension","volume":"10","author":"Kaminskas","year":"2005","journal-title":"Oncologist"},{"key":"10.1002\/hon.2054-BIB0002|hon2054-cit-0002","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/DDDT.S3143","article-title":"Safety and efficacy of azacitidine in myelodysplastic syndromes","volume":"4","author":"Vigil","year":"2010","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"10.1002\/hon.2054-BIB0003|hon2054-cit-0003","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.leukres.2012.04.024","article-title":"Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review","volume":"36","author":"Thorpe","year":"2012","journal-title":"Leuk Res"},{"issue":"12","key":"10.1002\/hon.2054-BIB0004|hon2054-cit-0004","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia","volume":"117","author":"Costa","year":"2011","journal-title":"Cancer"},{"issue":"7","key":"10.1002\/hon.2054-BIB0005|hon2054-cit-0005","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.leukres.2012.03.026","article-title":"Azacitidine differentially affects CD4(pos) T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes","volume":"36","author":"Bontkes","year":"2012","journal-title":"Leuk Res"},{"issue":"Suppl 2","key":"10.1002\/hon.2054-BIB0006|hon2054-cit-0006","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/10428194.2011.565097","article-title":"Purine analog toxicity in patients with hairy cell leukemia","volume":"52","author":"Tadmor","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"5-6","key":"10.1002\/hon.2054-BIB0007|hon2054-cit-0007","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3109\/10428199509059649","article-title":"Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas","volume":"18","author":"Fenchel","year":"1995","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1002\/hon.2054-BIB0008|hon2054-cit-0008","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/modpathol.2009.131","article-title":"Immunomodulator agent-related lymphoproliferative disorders","volume":"22","author":"Hasserjian","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1002\/hon.2054-BIB0009|hon2054-cit-0009","first-page":"350","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Gaulard","year":"2008"},{"issue":"5","key":"10.1002\/hon.2054-BIB0010|hon2054-cit-0010","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/10428190310001625890","article-title":"Epstein-Barr virus positive large B-cell lymphoma arising in a patient previously treated with Cladribine for hairy cell leukemia","volume":"45","author":"Bhargava","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1002\/hon.2054-BIB0011|hon2054-cit-0011","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1182\/blood-2003-07-2494","article-title":"Epstein-Barr virus-associated B-cell non-Hodgkin lymphoma following treatment of hairy cell leukemia with cladribine","volume":"102","author":"Lenz","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1002\/hon.2054-BIB0012|hon2054-cit-0012","first-page":"322","article-title":"Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication","volume":"34","author":"Hoshida","year":"2007","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1002\/hon.2054-BIB0013|hon2054-cit-0013","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1097\/00007890-199911270-00015","article-title":"Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS\/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting","volume":"68","author":"Paya","year":"1999","journal-title":"Transplantation"},{"issue":"5","key":"10.1002\/hon.2054-BIB0014|hon2054-cit-0014","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1634\/theoncologist.2008-0036","article-title":"EBV-associated lymphoproliferative disorders: classification and treatment","volume":"13","author":"Carbone","year":"2008","journal-title":"Oncologist"},{"issue":"8","key":"10.1002\/hon.2054-BIB0015|hon2054-cit-0015","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00007890-200210270-00007","article-title":"Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome","volume":"74","author":"Dotti","year":"2002","journal-title":"Transplantation"},{"issue":"1408","key":"10.1002\/hon.2054-BIB0016|hon2054-cit-0016","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1098\/rstb.2000.0783","article-title":"Biology and disease associations of Epstein-Barr virus","volume":"356","author":"Crawford","year":"2001","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"5","key":"10.1002\/hon.2054-BIB0017|hon2054-cit-0017","doi-asserted-by":"crossref","first-page":"e1001337","DOI":"10.1371\/journal.ppat.1001337","article-title":"Clonal structure of rapid-onset MDV-driven CD4+ lymphomas and responding CD8+ T cells","volume":"7","author":"Mwangi","year":"2011","journal-title":"PLoS Pathog"},{"issue":"7077","key":"10.1002\/hon.2054-BIB0018|hon2054-cit-0018","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"issue":"8","key":"10.1002\/hon.2054-BIB0019|hon2054-cit-0019","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/nm0896-906","article-title":"Large clonal expansions of CD8+ T cells in acute infectious mononucleosis","volume":"2","author":"Callan","year":"1996","journal-title":"Nat Med"},{"issue":"5","key":"10.1002\/hon.2054-BIB0020|hon2054-cit-0020","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00000478-200205000-00009","article-title":"Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms","volume":"26","author":"Abruzzo","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1002\/hon.2054-BIB0021|hon2054-cit-0021","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.humpath.2010.04.019","article-title":"Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia\/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative disorder with evidence suggestive of multiclonal transformability of B cells by Epstein-Barr virus","volume":"41","author":"Foo","year":"2010","journal-title":"Hum Pathol"},{"issue":"11","key":"10.1002\/hon.2054-BIB0022|hon2054-cit-0022","first-page":"1151","article-title":"Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment","volume":"10","author":"Shields","year":"1997","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1002\/hon.2054-BIB0023|hon2054-cit-0023","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"International Vidaza high-risk MDSSSG. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2054","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/hon.2054\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T20:14:22Z","timestamp":1625170462000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2054"}},"subtitle":["EBV-LPD after Azacitidine therapy"],"short-title":[],"issued":{"date-parts":[[2013,4,29]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"URL":"https:\/\/doi.org\/10.1002\/hon.2054","relation":{},"ISSN":["0278-0232"],"issn-type":[{"value":"0278-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4,29]]}}}